Impact of blockers of AT1 receptors to angiotensin II on endothelium vasoregulating function in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 739s Year: 2006
Cardiohemodynamics changes in COPD patients while using blockers of AT1 receptors to angiotensin II Source: Eur Respir J 2006; 28: Suppl. 50, 105s Year: 2006
Evaluation in administration of angiotensin II receptor antagonist Valsartan in the treatment of hypertension patients with chronic obstructive pulmonary disease. Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019
Anti-asthmatic effects of losartan, a blocker of angiotensin II type 1 receptor, in a rat model of allergic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
Impact of statins, angiotensin-converting enzyme inhibitors(ACEI), and angiotensin receptor blockers (ARBs) on reducing COPD morbidity Source: Annual Congress 2010 - COPD: management Year: 2010
Impact of statins, angiotensin-converting enzyme inhibitors (ACEI), and angiotensin receptor blockers (ARBS) on reducing COPD morbidity Source: Annual Congress 2009 - Treatment of airways disease Year: 2009
Angiotensin II receptor blockers, ACE inhibitors, lung function and percent emphysema; the MESA lung study Source: Annual Congress 2012 - Asthma and COPD: quality of life and comorbidities Year: 2012
Severe pulmonary hypertension in chronic lung disease. Long term effects on gas exchange of endothelin receptor antagonists or PDE5 inhibitors Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011
Association of cardiovascular risk with inhaled long-acting anti-muscarinic antagonists in COPD patients with impaired renal function Source: International Congress 2018 – Cardiovascular morbidities in COPD Year: 2018
Role of angiotensin receptors in the preclinical cardiovascular risk in obstructive sleep apnea patients Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases Year: 2017
A potential new therapy for pulmonary hypertension with the use of compound 21, an angiotensin type 2 receptor (AT2R) agonist Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Inhalation of endothelin receptor blockers in pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
Effects of AT1 receptor blockade on pulmonary and systemic manifestations in a COPD/emphysema mouse model Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists Source: Eur Respir Monogr 2020; 88: 238-250 Year: 2020
Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011
Late Breaking Abstract: Angiotensin II receptor blocker is associated with lower mortality in hospitalized patients with pneumonia Source: Annual Congress 2010 - From rare towards common lung diseases: diagnostic and monitoring challenges Year: 2010
Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008
C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015
Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007
Effect of long-term angiotensin-converting factor inhibitors on breathing function and hemorheology indices in patients with tuberculosis and COPD Source: Eur Respir J 2001; 18: Suppl. 33, 306s Year: 2001